RFC1 Activators

The chemical class of RFC1 activators, as suggested here, is diverse, reflecting the indirect approach needed to influence RFC1 activity. These chemicals primarily target various aspects of DNA replication, repair, and cell cycle regulation. The first group includes DNA synthesis inhibitors like Aphidicolin and Hydroxyurea, which modulate the demand for PCNA loading, a process where RFC1 is directly involved. By altering the replication stress, these compounds indirectly impact RFC1's function in the replication machinery.

The second group comprises DNA-damaging agents such as Camptothecin, Etoposide, Cisplatin, and Doxorubicin. These compounds induce DNA lesions that require repair mechanisms where RFC1 might be indirectly involved. For instance, Camptothecin and Etoposide target topoisomerases, essential for relieving DNA supercoiling during replication and transcription. Cisplatin and Doxorubicin cause DNA crosslinking and intercalation, respectively, leading to DNA damage that necessitates repair pathways, potentially involving RFC1. Additionally, compounds like Olaparib, a PARP inhibitor, and Bortezomib, a proteasome inhibitor, represent another aspect of this chemical class. They influence cellular pathways related to DNA repair and protein homeostasis, thus indirectly affecting RFC1's activity. For example, Olaparib's inhibition of PARP alters the DNA repair processes, possibly impacting RFC1's role in these pathways.